Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
This is an open phase I clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamic (PD) profile, immunogenicity, and preliminary efficacy of JS203 in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma. The study is divided into three phases: a dose-escalation phase, a dose-expansion phase, and an efficacy expansion phase.
• Understand and voluntarily sign the informed consent form.
• Age 18 - 75 years (both 18 and 75 years), both sexes
• Expected survival of ≥ 12 weeks.
• Eastern Collaborative Oncology Group (ECOG) physical status score: 0 to 1.
• B-cell non-Hodgkin's lymphoma expressing CD20 antigen clearly diagnosed by pathology
• Patients with non-Hodgkin's lymphoma must have measurable lesions that meet the Lugano 2014 criteria for lymphoma efficacy assessment, requiring lymph node lesions \>1.5 cm in either length or extra-nodal lesions \>1.0 cm in either length.